Prion Disease Cure Roadmap provides a comprehensive framework for therapeutic development for prion diseases, also known as transmissible spongiform encephalopathies (TSEs). Prion diseases are unique in that they are caused by a protein-only infectious agent — the prion protein (PrP^Sc) — which is an aggregated, misfolded conformer of the normal cellular prion protein (PrP^C).
Prion diseases affect both humans and animals:
- Human: Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), kuru, variant CJD (vCJD), GSS syndrome
- Animal: Bovine spongiform encephalopathy (BSE), scrapie (sheep), chronic wasting disease (CWD) (deer, elk)
The fundamental challenge is that prions propagate by template-driven conformational conversion of normal PrP^C to the infectious PrP^Sc form, and this process is inherently self-reinforcing — making it exceptionally difficult to interrupt.
¶ Current Therapeutic Landscape
No disease-modifying or curative treatments are approved for any human prion disease.
Palliative care focuses on:
- Symptom management (myoclonus, insomnia, dysphagia)
- Nutritional support
- Prevention of aspiration pneumonia
| Drug |
Mechanism |
Trial Result |
| Quinacrine |
Anti-prion activity in cell models |
No clinical benefit (CJD) |
| Pentosan polysulfate |
Prion binding |
No survival benefit |
| Amphotericin B |
Anti-prion |
No benefit |
| Doxycycline |
Anti-aggregation |
Mixed results |
| Flupirtine |
Neuroprotection |
No benefit |
- PRN2008 (ProMab): Anti-PrP monoclonal antibody in early-phase trials
- Anle305b (Universität Tübingen): Prion aggregation inhibitor in preclinical/Phase 1
The core therapeutic strategy is preventing the conversion of PrP^C to PrP^Sc:
flowchart TD
A["PrP^C (Normal)"] --> B["Prion Conversion"]
B --> C["PrP^Sc (Infectious)"]
B --> D["Toxic Oligomers"]
C --> E["Neurodegeneration"]
D --> E
B --> F["Conversion Inhibitors"]
F --> F1["Small molecules"]
F --> F2["Antibodies"]
F --> F3["Peptides"]
C --> G["Clearance"]
G --> G1["Antibodies"]
G --> G2["Autophagy enhancers"]
Approaches:
- Small molecules: Polyanionic compounds, aromatic heterocycles
- Antibodies: Anti-PrP monoclonal antibodies (blocking conversion)
- Peptide-based: PrP-derived sequences that block template
Once prions have formed, removing them requires:
- Immunotherapy: Anti-PrP antibodies to clear existing aggregates
- Autophagy enhancers: Rapamycin, trehalose to boost protein clearance
- Protein degradation: PROTACs targeting PrP
Since prion toxicity involves multiple pathways:
- ER stress inhibitors: Salubrinal, ISRIB
- Mitochondrial protectants: CoQ10, SS-31
- Anti-inflammatory: Minocycline (cautiously)
- Synaptic preservation: BDNF, synaptic stabilizers
- PRNP knockdown: ASO or siRNA to reduce PrP^C expression
- PRNP editing: CRISPR-based approaches
- Resistance mutations: Identify protective PRNP variants
| Biomarker |
Target |
Status |
| 14-3-3 protein |
CSF |
Widely used, moderate specificity |
| Tau protein |
CSF |
Elevated in CJD |
| RT-QuIC |
CSF/tissue |
High sensitivity/specificity |
| Real-time quaking-induced conversion (RT-QuIC) |
Nasal brush, skin |
Emerging |
| PrP^Sc detection |
Tissue |
Gold standard (post-mortem) |
- Neurofilament light chain (NfL): Blood/CSF marker of neurodegeneration
- Neurogranin: Synaptic damage
- YKL-40: Microglial activation
For genetic prion disease (PRNP mutations):
- Presymptomatic genetic testing available
- Biomarker monitoring in carriers (NfL, RT-QuIC)
- Intervention timing critical — treat before symptoms
- Rapid disease progression: CJD median survival 4-6 months
- Diagnostic uncertainty: Require definite/probable CJD
- Heterogeneous disease: Sporadic, genetic, iatrogenic, variant
- Limited patient numbers: Rare disease
- No validated surrogate endpoints
- Target pre-symptomatic genetic carriers
- Early-stage symptomatic patients
- Exclude rapidly progressive cases
- Require positive RT-QuIC
| Domain |
Measure |
Notes |
| Survival |
Primary: time to death |
Challenging with rapid progression |
| Cognition |
MMSE, CDR |
Floor effects |
| Motor |
MRS, neurological exam |
Myoclonus tracking |
| Biomarker |
NfL, tau, RT-QuIC |
Surrogate potential |
- Adaptive platform trials: Multiple agents simultaneously
- Master protocol: Umbrella trials for CJD subtypes
- Pre-symptomatic trials: In genetic carriers
¶ Research Gaps and Priorities
- Prion strain diversity — how different strains cause different phenotypes
- Cell-to-cell transmission mechanism — how prions spread between neurons/glia
- Neurotoxic species identification — which PrP^Sc form causes damage
- Biomarker validation — for early detection and treatment response
- Combination therapy — synergy between conversion inhibitors and clearance
- Anti-PrP antibodies — Phase 1/2 results (PRN2008)
- Prion aggregation inhibitors — early trials (Anle305b)
- RT-QuIC optimization — for treatment response
- First disease-modifying therapy — likely immunotherapy combination
- Genetic carrier intervention — pre-symptomatic treatment protocols
- Biomarker-driven patient selection — for clinical trials
- Prevention in genetic carriers — early intervention before conversion
- Cure through gene therapy — PRNP editing or knockdown
- Combination approaches — inhibitors + clearance + neuroprotection